about
Regulation of EPCs: The Gateway to Blood Vessel FormationCilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury modelCilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCĪµ and to Activate p44/42 MAPK in Human Aortic Endothelial CellsCilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbitsImproved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylateChronotropic effect of the antithrombotic agent cilostazol in a patient with sick sinus syndrome and syncope.Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive ratsPhosphodiesterase-3 inhibitor (cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart.RETRACTED: Systematic study of cilostazol on secondary stroke prevention: a meta-analysisCilostazol Inhibits Vascular Smooth Muscle Cell Proliferation and Reactive Oxygen Species Production through Activation of AMP-activated Protein Kinase Induced by Heme Oxygenase-1.Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis.cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.Cilostazol Decreases Ethanol-Mediated TNFalpha Expression in RAW264.7 Murine Macrophage and in Liver from Binge Drinking MiceIt Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting StentCyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.A review of the role of anticoagulation in the treatment of peripheral arterial disease.Efficacy of cilostazol on uncontrolled coronary vasospastic angina: a pilot study.Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial.Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.Targeting cancer with phosphodiesterase inhibitors.Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke.Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs.Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.Use of cilostazol for secondary stroke prevention: an old dog with new tricks?Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.The role of the host defense system in the development of cerebral vasospasm: analogies between atherosclerosis and subarachnoid hemorrhage.Inflammation, vasospasm, and brain injury after subarachnoid hemorrhage.Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study.Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event.Effect of cilostazol in the treatment of acute ischemic stroke in the lenticulostriate artery territory.A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats.Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.Cilostazol attenuates kainic acid-induced hippocampal cell death.Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats.Haematoma scavenging in intracerebral haemorrhage: from mechanisms to the clinic.Basic in vitro Characterization of the Vasodilatory Potential of 2-Aminoethyl Nitrate Fixed-Dose Combinations with Cilostazol, Metoprolol and Valsartan.
P2860
Q21284530-455330AA-1F78-414C-B67F-CD020E0D3AADQ28477044-506B2E11-2582-412A-B669-CA2412273D9EQ28546598-167669C4-4876-497A-9736-012E15CC4F53Q28728089-81D76FF5-0ED3-4424-9DAD-F8FB585D5A07Q30985734-D16AC0AC-6337-42BC-9BBE-F343A5A9A239Q33151864-4C482980-FD9D-4834-929F-A53BFF8893BBQ33509003-090CAB68-C4EA-4E4E-9B74-D3B01424490CQ33826557-D033AA3F-48B6-4546-9FD1-6564C2F08931Q35061792-8A94A2EE-616E-4EBD-9FF6-65D69009D110Q35270041-F0127200-3A97-423E-B973-C2C97C4D7E5AQ35620767-92B1C987-564C-4471-9B66-014B9D25481AQ35687052-E7F58C14-E653-42CC-8392-86DFEB75DA21Q35919812-65271AA9-3A6D-4465-BD4E-F9AF5D65BD81Q36299313-375432B2-D266-410E-B791-B70C21CA6B74Q36334968-3A68F3EB-8AE9-4578-8D83-1157FC0AEB3CQ36627535-1CA9E2B1-FC25-45EE-8004-C711A11D87F7Q36844494-1E9B383D-E81E-42DD-8CD4-34C8DF6D28C1Q37070954-3B28B00E-C1E5-44A0-9928-322758CA858EQ37164669-114DE889-75DE-4864-A12E-D38A32DBA468Q37650389-961B303F-A336-47C7-8058-7400A766BE78Q37690863-E8B89D66-45F0-40C3-B72E-BB969F455F1AQ37723799-449B6A94-5EBD-4245-89C3-EF25EC76B865Q37971308-A268F6E1-E6D7-429D-B98A-8E7123689F1BQ37986922-E0B528C8-43A1-4B36-9CAE-369E1E818E79Q38029492-86654BA0-98BB-49CF-8557-3D34A5B8C221Q38055310-891A4C8C-AD75-49DD-85C5-45A76526EE4DQ41958830-6C78942A-11FF-4EB7-8F99-73F5F2E9D48AQ42385835-52C55636-3A82-4E17-858C-A55C950CD551Q43829075-92FA172B-C3F5-41F5-B645-DEE83B9F5E26Q43914580-83FE8CD5-8EF8-4D7B-9C39-124EE90B826AQ44571740-8A82CA65-E7E7-48EC-9B44-E913BA113458Q44941582-7A514A9E-CAF8-4B9A-8188-588601BA98E2Q46502774-F8028ACD-4999-4F91-8DDE-9EFCBDA10198Q46680292-FD47B0B7-DA44-4802-AED8-96F180683A53Q47123849-51438AA3-A6B6-4CBA-BD74-91311F2B5845Q47275749-DD2092CF-2446-47D2-B248-54758BDE2D87Q47288494-C8826618-3262-4A86-8F4C-660F4C182994Q47698798-6BFF0C1A-3AEB-4AFB-BB7F-936FD9F6C601Q47895434-CF60BC4F-B355-41EC-BA12-021795F9B526Q49502212-A01278CC-63C2-4858-9DBD-3DB2B0483F30
P2860
description
2003 nĆ® lÅ«n-bĆ»n
@nan
2003 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¶ÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2003 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¶Õ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2003幓ć®č«ę
@ja
2003幓č«ę
@yue
2003幓č«ę
@zh-hant
2003幓č«ę
@zh-hk
2003幓č«ę
@zh-mo
2003幓č«ę
@zh-tw
2003幓č®ŗę
@wuu
name
Cilostazol as a unique antithrombotic agent.
@ast
Cilostazol as a unique antithrombotic agent.
@en
type
label
Cilostazol as a unique antithrombotic agent.
@ast
Cilostazol as a unique antithrombotic agent.
@en
prefLabel
Cilostazol as a unique antithrombotic agent.
@ast
Cilostazol as a unique antithrombotic agent.
@en
P2093
P356
P1476
Cilostazol as a unique antithrombotic agent.
@en
P2093
Frank Czerwiec
Junichi Kambayashi
Masuhiro Yoshitake
Yasmin Shakur
Yongge Liu
P304
P356
10.2174/1381612033453910
P577
2003-01-01T00:00:00Z